Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies

Exclusion Criteria

• •1. Subject has evidence of clinically significant liver disease.
• •2. Subject has evidence of clinically significant renal disease.
• •3. Presence of significant comorbidities or conditions other than CNM or clinically significant findings during screening of medical history, physical examination, clinical laboratory evaluation, vital signs, or ECG recording for which, in the opinion of the investigator and/or the medical monitor, participation would not be in the best interest of the subject (e.g. compromise the safety or well-being) or that could prevent, limit, or confound the protocol-specified assessments (e.g. taking a muscle biopsy).
• •4. Subject currently enrolled in any interventional trial or scheduled to participate in such a trial whilst participating in the current trial.
• •5. Subject has previously received gene therapy for CNM.
• •6. Subject has severe muscle contractures that would preclude the ability to show improvement in the MFM32 assessment, in the opinion of the investigator.
• •7. Subject has severe airway malacia which could impact the capacity to wean off ventilatory support.
• •8. Subject requires oxygen supplementation.
• •9. For female subjects of childbearing potential: pregnant, breastfeeding, or planning to become pregnant during the trial.
• •10. Current or relevant history of physical or psychiatric illness, and/or any medical disorder that may require treatment or make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the investigational medicinal product (IMP) or procedures.
• •11. Intake of any disallowed therapies by the subject within 12 weeks before the planned first IMP administration.
• •12. Known or suspected intolerance or hypersensitivity to IMP ingredients or closely related compounds.
• •13. Parent(s) or legally authorized representative are legally incapacitated or have limited legal capacity, or have lack of mental capacity to fully understand the protocol requirements and ensure completion of all required trial procedures.